Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2024 Jan 10

PMID 38198112

Authors

Fei Song

Paolo Tarantino

Ana Garrido-Castro

Filipa Lynce

Sara M Tolaney

Ilana Schlam

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: In this narrative review, we discuss the optimal timing of immune checkpoint inhibitors (ICI) in early triple negative breast cancer (TNBC), the landscape of predictive biomarkers for the use of immunotherapy, and the mounting literature suggesting a benefit for an early use of ICI.

Recent Findings: TNBC is associated with a poor prognosis relative to other breast cancer subtypes, and until recently, the treatment of TNBC was limited to cytotoxic chemotherapy. In 2021, the immune-checkpoint inhibitor, pembrolizumab, was approved in combination with neoadjuvant chemotherapy for patients with high-risk early stage TNBC. This approval changed the treatment paradigm of early TNBC concomitantly raised several challenges in clinical practice, pertaining to patient selection, toxicity management, and post-neoadjuvant treatment, among others. The introduction of neoadjuvant chemoimmunotherapy has transformed the treatment landscape for early TNBC. However, several challenges, including patient selection, toxicity management, and the identification of predictive biomarkers, need to be addressed. Future research should focus on refining the timing and duration of immunotherapy, optimizing the chemotherapy partner, and exploring novel predictive biomarkers of response or toxicity.

Citing Articles

Construction of a prognostic survival model with tumor immune-related genes for breast cancer.

Guo S, Guo L, Li J, Li J, Zhang Q, Zhang J Transl Cancer Res. 2025; 13(12):6919-6935.

PMID: 39816565 PMC: 11730693. DOI: 10.21037/tcr-24-2137.

The Application of Traditional Chinese Medicine-Derived Formulations in Cancer Immunotherapy: A Review.

Li Y, Li C, Fan J, Liu Y, Xu Y, Pang G Cancer Manag Res. 2025; 17():23-34.

PMID: 39816489 PMC: 11734505. DOI: 10.2147/CMAR.S503071.

Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features.

Boissiere-Michot F, Chateau M, Thezenas S, Lafont V, Crapez E, Sharma P Front Immunol. 2024; 15:1507371.

PMID: 39723208 PMC: 11669358. DOI: 10.3389/fimmu.2024.1507371.

References

Giaquinto A, Sung H, Miller K, Kramer J, Newman L, Minihan A . Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022; 72(6):524-541. DOI: 10.3322/caac.21754. View

Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J . Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020; 382(9):810-821. DOI: 10.1056/NEJMoa1910549. View

Mauri D, Pavlidis N, Ioannidis J . Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97(3):188-94. DOI: 10.1093/jnci/dji021. View

Fraser Symmans W, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V . Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007; 25(28):4414-22. DOI: 10.1200/JCO.2007.10.6823. View

Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D . Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2021; 23(1):149-160. PMC: 9455620. DOI: 10.1016/S1470-2045(21)00589-1. View

Nanda R, Liu M, Yau C, Shatsky R, Pusztai L, Wallace A . Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020; 6(5):676-684. PMC: 7058271. DOI: 10.1001/jamaoncol.2019.6650. View

Loibl S, Untch M, Burchardi N, Huober J, Sinn B, Blohmer J . A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019; 30(8):1279-1288. DOI: 10.1093/annonc/mdz158. View

Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer J . Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022; 33(11):1149-1158. DOI: 10.1016/j.annonc.2022.07.1940. View

Gianni L, Huang C, Egle D, Bermejo B, Zamagni C, Thill M . Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022; 33(5):534-543. DOI: 10.1016/j.annonc.2022.02.004. View

10.

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S . Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022; 386(6):556-567. DOI: 10.1056/NEJMoa2112651. View

11.

Liu J, Blake S, Yong M, Harjunpaa H, Ngiow S, Takeda K . Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016; 6(12):1382-1399. DOI: 10.1158/2159-8290.CD-16-0577. View

12.

Faramarzi S, Ghafouri-Fard S . Melanoma: a prototype of cancer-testis antigen-expressing malignancies. Immunotherapy. 2017; 9(13):1103-1113. DOI: 10.2217/imt-2017-0091. View

13.

Patel S, Othus M, Chen Y, Wright Jr G, Yost K, Hyngstrom J . Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023; 388(9):813-823. PMC: 10410527. DOI: 10.1056/NEJMoa2211437. View

14.

Blank C, Rozeman E, Fanchi L, Sikorska K, van de Wiel B, Kvistborg P . Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018; 24(11):1655-1661. DOI: 10.1038/s41591-018-0198-0. View

15.

Forde P, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad M . Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022; 386(21):1973-1985. PMC: 9844511. DOI: 10.1056/NEJMoa2202170. View

16.

OBrien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L . Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022; 23(10):1274-1286. DOI: 10.1016/S1470-2045(22)00518-6. View

17.

Yoest J . Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. Immunotargets Ther. 2017; 6:73-82. PMC: 5644546. DOI: 10.2147/ITT.S126227. View

18.

Bianchini G, De Angelis C, Licata L, Gianni L . Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2021; 19(2):91-113. DOI: 10.1038/s41571-021-00565-2. View

19.

Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho J . Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell. 2022; 185(10):1694-1708.e19. PMC: 11332067. DOI: 10.1016/j.cell.2022.03.033. View

20.

Emens L, Molinero L, Loi S, Rugo H, Schneeweiss A, Dieras V . Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. J Natl Cancer Inst. 2021; 113(8):1005-1016. PMC: 8328980. DOI: 10.1093/jnci/djab004. View